Real-world effectiveness of adjuvanted RSVPreF3 vaccine in preventing RSV-associated lower respiratory tract disease hospitalization in adults ≥60 years of age: early results from a test-negative design analysis

Puntos clave

• This research aims to evaluate the effectiveness of the adjuvanted RSVPreF3 vaccine in preventing RSV-related hospitalizations in adults aged 60 and older.
• Test-negative design analysis conducted from Dec 2023 to Feb 2025.
• Assessing adults aged ≥60 years with laboratory-confirmed RSV-related hospitalizations.
• Evaluating vaccine effectiveness within the season.
• Overall vaccine effectiveness (VE) estimated at 82.3%.
• VE for subgroups ranged from 81.0% to 92.1%.
• Effective protection noted particularly among individuals at increased risk of severe RSV disease.